EUVIMEDUpptäck EUVIMED
Open access · CC BY-NC-ND 4.0

Predicting Efficacy of Immune Checkpoint Inhibitors in Targeted Oncology Therapy using Multi-Modal Deep Learning

James Smith, Robert Anderson, William Miller

Frontiers in Healthcare Technology · 2026-01-18 · 3 (1) · 31-39

DOI: 10.71465/fht613 ↗

At a glance

Journal article in Frontiers in Healthcare Technology, published online on 2026-01-18. Written by James Smith and 2 co-authors. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractBibliografiska uppgifterCiteRelated studies

Abstract (original language)

The advent of immune checkpoint inhibitors has revolutionized the landscape of oncological treatment, particularly for solid tumors such as melanoma and non-small cell lung cancer. However, the efficacy of these therapies remains heterogeneous, with a significant fraction of patients failing to exhibit a durable objective response. Traditional biomarkers, including PD-L1 expression levels and tumor mutational burden, lack the requisite sensitivity and specificity to accurately stratify patients in a clinical setting. This paper proposes a comprehensive multi-modal deep learning framework designed to predict the therapeutic efficacy of immune checkpoint inhibitors by integrating whole slide histopathology images, genomic sequencing data, and baseline clinical demographics. By employing a late-fusion architecture that utilizes attention mechanisms to weigh the relative importance of distinct modalities, the proposed model captures the complex non-linear interactions between the tumor microenvironment and the host immune system. Experimental results on a large-scale retrospective cohort demonstrate that this multi-modal approach significantly outperforms unimodal baselines and current standard-of-care biomarkers. The study provides a pathway toward precision immuno-oncology, highlighting the critical role of artificial intelligence in deciphering the biological heterogeneity of cancer response mechanisms.

Cite

APA

Smith, J., Anderson, R., & Miller, W. (2026). Predicting Efficacy of Immune Checkpoint Inhibitors in Targeted Oncology Therapy using Multi-Modal Deep Learning. Frontiers in Healthcare Technology, 3(1), 31-39. https://doi.org/10.71465/fht613

Vancouver

Smith J, Anderson R, Miller W. Predicting Efficacy of Immune Checkpoint Inhibitors in Targeted Oncology Therapy using Multi-Modal Deep Learning. Frontiers in Healthcare Technology. 2026;3(1):31-39. doi:10.71465/fht613

BibTeX
@article{Smith2026,
  author = {Smith, James and Anderson, Robert and Miller, William},
  title = {Predicting Efficacy of Immune Checkpoint Inhibitors in Targeted Oncology Therapy using Multi-Modal Deep Learning},
  journal = {Frontiers in Healthcare Technology},
  year = {2026},
  volume = {3},
  number = {1},
  pages = {31--39},
  doi = {10.71465/fht613}
}
Start for free →